Literature DB >> 30392569

Reduced exosome miR-425 and miR-744 in the plasma represents the progression of fibrosis and heart failure.

Lu Wang1, Jiao Liu2, Bin Xu3, Yu-Lan Liu2, Zhou Liu2.   

Abstract

Heart failure creates a leading public health burden worldwide and cardiac fibrosis is a hallmark of pathological cardiac remodeling which was found in HF patients. In this study, we detected the expression of 9 candidate miRNAs in the plasma exosome samples from 31 HF patients, and found the level of miR-21, miR-425 and miR-744 was altered. The downregulation of miR-425 and miR-744 was also found in angiotensin II treated cardiac fibroblasts. Through functional study, we identified that the reduction of miR-425 and miR-744 relates to overexpression of collagen 1 and α-SMA, which result in fibrogenesis of cardiac fibroblasts. Conversely, overexpression of miR-425 or miR-744 in cultured cardiac fibroblasts significantly abrogates angiotensin induced collagen formation and fibrogenesis. Finally, we confirmed that TGFβ1 is a direct target of miR-425 and miR-744 by dual luciferase assay and immunoblotting. Our data demonstrate that miR-425 and miR-744 function as negative regulators of cardiac fibrosis by suppression TGFβ1 expression, and miR-425 and miR-744 level in the plasma exosomes has the potential to be a biomarker to predict cardiac fibrosis and heart failure.
Copyright © 2018. Published by Elsevier Taiwan LLC.

Entities:  

Keywords:  EGFβ1; Fibrosis; Heart failure; miRNA

Mesh:

Substances:

Year:  2018        PMID: 30392569     DOI: 10.1016/j.kjms.2018.05.008

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  22 in total

Review 1.  Progress in exosomes and their potential use in ocular diseases.

Authors:  Su-Fang Li; Ying Han; Feng Wang; Ying Su
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

Review 2.  New Approaches for Enhancement of the Efficacy of Mesenchymal Stem Cell-Derived Exosomes in Cardiovascular Diseases.

Authors:  Lamiaa Ahmed; Khaled Al-Massri
Journal:  Tissue Eng Regen Med       Date:  2022-07-22       Impact factor: 4.451

3.  The Peripheral Circulating Exosomal microRNAs Related to Central Inflammation in Chronic Heart Failure.

Authors:  Yu-Chen Xiao; Wen Wang; Yuan Gao; Wan-Yang Li; Xing Tan; Yang-Kai Wang; Wei-Zhong Wang
Journal:  J Cardiovasc Transl Res       Date:  2022-05-02       Impact factor: 3.216

Review 4.  Diagnostic and Therapeutic Properties of Exosomes in Cardiac Fibrosis.

Authors:  Jiwen Fan; Meng Ren; Yuquan He
Journal:  Front Cell Dev Biol       Date:  2022-07-04

Review 5.  Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials.

Authors:  Yuncong Shi; Huanji Zhang; Suli Huang; Li Yin; Feng Wang; Pei Luo; Hui Huang
Journal:  Signal Transduct Target Ther       Date:  2022-06-25

6.  The microRNA Expression Profiling in Heart Failure: A Systematic Review and Meta-Analysis.

Authors:  Nan-Nan Shen; Jia-Liang Wang; Yong-Ping Fu
Journal:  Front Cardiovasc Med       Date:  2022-06-15

7.  Differentially expressed miRNAs in circulating exosomes between atrial fibrillation and sinus rhythm.

Authors:  Suyu Wang; Jie Min; Yue Yu; Liang Yin; Qing Wang; Hua Shen; Jie Yang; Peng Zhang; Jian Xiao; Zhinong Wang
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

Review 8.  Epigenetic Biomarkers in Cardiovascular Diseases.

Authors:  Carolina Soler-Botija; Carolina Gálvez-Montón; Antoni Bayés-Genís
Journal:  Front Genet       Date:  2019-10-09       Impact factor: 4.599

Review 9.  Extracellular Vesicles in Organ Fibrosis: Mechanisms, Therapies, and Diagnostics.

Authors:  David R Brigstock
Journal:  Cells       Date:  2021-06-25       Impact factor: 6.600

Review 10.  The role of extracellular vesicles in regulating local and systemic inflammation in cardiovascular disease.

Authors:  Lee Ohayon; Xinyi Zhang; Partha Dutta
Journal:  Pharmacol Res       Date:  2021-06-25       Impact factor: 10.334

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.